Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials

Katherine R Tuttle, Adeera Levin, Masaomi Nangaku, Takashi Kadowaki, Rajiv Agarwal, Sibylle J Hauske, Amelie Elsäßer, Ivana Ritter, Dominik Steubl, Christoph Wanner, David C Wheeler, Katherine R Tuttle, Adeera Levin, Masaomi Nangaku, Takashi Kadowaki, Rajiv Agarwal, Sibylle J Hauske, Amelie Elsäßer, Ivana Ritter, Dominik Steubl, Christoph Wanner, David C Wheeler

Abstract

Objective: To assess the safety of empagliflozin in patients with type 2 diabetes and moderate to severe chronic kidney disease (CKD) (category G3-4) enrolled in clinical trials.

Research design and methods: This analysis pooled data from 19 randomized, placebo-controlled, phase 1-4 clinical trials and 1 randomized, placebo-controlled extension study in which patients received empagliflozin 10 mg or 25 mg daily. Time to first occurrence of adverse events (AEs) was evaluated using Kaplan-Meier analysis and multivariable Cox regression models.

Results: Among a total of 15,081 patients who received at least one study drug dose, 1,522, 722, and 123 were classified as having G3A, G3B, and G4 CKD, respectively, at baseline. Demographic and clinical characteristics were similar between treatment groups across CKD categories. Rates of serious AEs, AEs leading to discontinuation, and events of special interest (including lower limb amputations and acute renal failure [ARF]) were also similar between empagliflozin and placebo across CKD subgroups. In adjusted Cox regression analyses, risks for volume depletion and ARF were similar for empagliflozin and placebo in the combined group with CKD categories G3B and G4 and the G3A group. Notably lower risks were observed in both groups for hyperkalemia (hazard ratio 0.59 [95% CI 0.37-0.96, P = 0.0323] and 0.48 [0.26-0.91, P = 0.0243], respectively) and edema (0.47 [0.33-0.68, P < 0.0001] and 0.44 [0.28-0.68, P = 0.0002], respectively).

Conclusions: Use of empagliflozin in patients with type 2 diabetes and advanced CKD raised no new safety concerns and may have beneficial effects on the development of hyperkalemia and edema.

Trial registration: ClinicalTrials.gov NCT03594110 NCT00885118 NCT00789035 NCT00558571 NCT00749190 NCT01011868 NCT01193218 NCT01210001 NCT01177813 NCT01159600 NCT01289990 NCT01131676 NCT01164501 NCT01370005 NCT01306214 NCT01649297 NCT01947855 NCT02589639.

© 2022 by the American Diabetes Association.

Figures

Figure 1
Figure 1
Kaplan-Meier estimates of time to first event of hyperkalemia (A), volume depletion (B), edema (C), and ARF (D) in patients with eGFR <45 mL/min/1.73 m2 (left) and 45 to <60 mL/min/1.73 m2 (right). eGFR was calculated using the CKD-EPI equation.

References

    1. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol 2017;12:2032–2045
    1. Bailey RA, Wang Y, Zhu V, Rupnow MF. Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: improving Global Outcomes (KDIGO) staging. BMC Res Notes 2014;7:415.
    1. De Cosmo S, Viazzi F, Pacilli A, et al. .; AMD-Annals Study Group . Predictors of chronic kidney disease in type 2 diabetes: a longitudinal study from the AMD Annals initiative. Medicine (Baltimore) 2016;95:e4007.
    1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group . KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1–150
    1. United States Renal Data System . 2019 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. Accessed 21 April 2022. Available from
    1. Matsushita K, van der Velde M, Astor BC, et al. .; Chronic Kidney Disease Prognosis Consortium . Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073–2081
    1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296–1305
    1. Barnett AH, Mithal A, Manassie J, et al. .; EMPA-REG RENAL Trial Investigators . Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014;2:369–384
    1. JARDIANCE [package insert] . Burlington, ON, Canada, Boehringer Ingelheim (Canada) Ltd., 2020
    1. Packer M, Anker SD, Butler J, et al. .; EMPEROR-Reduced Trial Investigators . Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413–1424
    1. Zinman B, Wanner C, Lachin JM, et al. .; EMPA-REG OUTCOME Investigators . Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–2128
    1. Wanner C, Inzucchi SE, Lachin JM, et al. .; EMPA-REG OUTCOME Investigators . Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323–334
    1. Wanner C, Lachin JM, Inzucchi SE, et al. .; EMPA-REG OUTCOME Investigators . Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 2018;137:119–129
    1. Kohler S, Zeller C, Iliev H, Kaspers S. Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials. Adv Ther 2017;34:1707–1726
    1. Inzucchi SE, Iliev H, Pfarr E, Zinman B. Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care 2018;41:e4–e5
    1. Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013;27:479–484
    1. Rosiak M, Grzeszczak S, Kosior DA, Postuła M. Emerging treatments in type 2 diabetes: focus on canagliflozin. Ther Clin Risk Manag 2014;10:683–689
    1. Schernthaner G, Drexel H, Moshkovich E, et al. . SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class. BMC Endocr Disord 2019;19:64.
    1. Macha S, Mattheus M, Halabi A, Pinnetti S, Woerle HJ, Broedl UC. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab 2014;16:215–222
    1. Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract 2014;103:373–381
    1. Neuen BL, Young T, Heerspink HJL, et al. . SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2019;7:845–854
    1. Perkovic V, Jardine MJ, Neal B, et al. .; CREDENCE Trial Investigators . Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295–2306
    1. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. .; DAPA-CKD Trial Committees and Investigators . Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383:1436–1446
    1. American Diabetes Association . 11. Microvascular complications and foot care: Standards of Medical Care in Diabetes–2021. Diabetes Care 2021;44(Suppl. 1):S151–S167
    1. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group . KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int Suppl 2020;98:S1–S115
    1. Wiviott SD, Raz I, Bonaca MP, et al. .; DECLARE–TIMI 58 Investigators . Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347–357
    1. Yavin Y, Mansfield TA, Ptaszynska A, Johnsson K, Parikh S, Johnsson E. Effect of the SGLT2 inhibitor dapagliflozin on potassium levels in patients with type 2 diabetes mellitus: a pooled analysis. Diabetes Ther 2016;7:125–137
    1. Oshima M, Jardine MJ, Agarwal R, et al. . Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney Int 2021;99:999–1009
    1. Weir MR, Slee A, Sun T, et al. . Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. Clin Kidney J 2020;14:1396–1402
    1. Agarwal R, Joseph A, Anker SD, et al. .; FIDELIO-DKD Investigators . Hyperkalemia risk with finerenone: results from the FIDELIO-DKD Trial. J Am Soc Nephrol 2022;33:225–237
    1. Bakris GL, Agarwal R, Anker SD, et al. .; FIDELIO-DKD Investigators . Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020;383:2219–2229
    1. Neal B, Perkovic V, Mahaffey KW, et al. .; CANVAS Program Collaborative Group . Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644–657
    1. Jardine MJ, Zhou Z, Mahaffey KW, et al. .; CREDENCE Study Investigators . Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial. J Am Soc Nephrol 2020;31:1128–1139

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit